HCM
ACAD icon

Hollencrest Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hollencrest Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Hold
1,000
– – ﹤0.01% 693
2026
Q1 		$22.3K Sell
1,000
-2,000
-67% -$47.8K ﹤0.01% 701
2025
Q4 		$80.1K Sell
3,000
-3,500
-54% -$83.6K ﹤0.01% 477
2025
Q3 		$139K Hold
6,500
– – 0.01% 375
2025
Q2 		$140K Hold
6,500
– – 0.01% 340
2025
Q1 		$108K Buy
6,500
+5,000
+333% +$90.8K ﹤0.01% 366
2024
Q4 		$27.5K Hold
1,500
– – ﹤0.01% 626
2024
Q3 		$23.1K Hold
1,500
– – ﹤0.01% 655
2024
Q2 		$24.4K Hold
1,500
– – ﹤0.01% 632
2024
Q1 		$27.7K Hold
1,500
– – ﹤0.01% 581
2023
Q4 		$47K Hold
1,500
– – ﹤0.01% 499
2023
Q3 		$31.3K Hold
1,500
– – ﹤0.01% 547
2023
Q2 		$35.9K Hold
1,500
– – ﹤0.01% 544
2023
Q1 		$28.2K Hold
1,500
– – ﹤0.01% 572
2022
Q4 		$23.9K Buy
+1,500
New +$23.4K ﹤0.01% 578
2018
Q1 		– Sell
-7,985
Closed -$241K – 332
2017
Q4 		$241K Hold
7,985
– – 0.03% 240
2017
Q3 		$301K Hold
7,985
– – 0.04% 223
2017
Q2 		$222K Sell
7,985
-1,000
-11% -$29.8K 0.03% 254
2017
Q1 		$309K Sell
8,985
-600
-6% -$21.2K 0.05% 242
2016
Q4 		$277K Sell
9,585
-17
-0.2% -$450 0.04% 226
2016
Q3 		$305K Sell
9,602
-3,000
-24% -$102K 0.04% 241
2016
Q2 		$409K Buy
12,602
+532
+4% +$17.8K 0.06% 213
2016
Q1 		$337K Sell
12,070
-2,000
-14% -$43.6K 0.06% 229
2015
Q4 		$501K Buy
14,070
+1,017
+8% +$35.8K 0.09% 189
2015
Q3 		$432K Buy
13,053
+207
+2% +$8.61K 0.07% 187
2015
Q2 		$538K Sell
12,846
-207
-2% -$8.01K 0.08% 179
2015
Q1 		$425K Hold
13,053
– – 0.06% 221
2014
Q4 		$414K Sell
13,053
-17,932
-58% -$509K 0.05% 239
2014
Q3 		$767K Sell
30,985
-19,000
-38% -$444K 0.1% 133
2014
Q2 		$1.13M Sell
49,985
-7,000
-12% -$146K 0.15% 107
2014
Q1 		$1.39M Hold
56,985
– – 0.21% 94
2013
Q4 		$1.42M Buy
+56,985
New +$1.34M 0.23% 86

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hollencrest Capital Management's ACAD Position: Q2 2026 in Review

Hollencrest Capital Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 1,000 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Hollencrest Capital Management first reported a position in ACAD in Q4 2013 and has held it in 32 quarters since. The position peaked at $1.42M in Q4 2013. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Hollencrest Capital Management held 1,000 shares of Acadia Pharmaceuticals worth $25.3K as of Q2 2026.
  • Hollencrest Capital Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #693 holding.
  • Hollencrest Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 32 quarters since.
  • Hollencrest Capital Management's Acadia Pharmaceuticals position peaked at $1.42M in Q4 2013.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.